Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | RBP4 | P02753 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133897 | 0.78 | MAPK1 (0.32) | MAPK1SMN1; SMN2DPP8DPP7 | |
| SCHEMBL797393 | 0.74 | KMT2A (0.42) | RAB9ANPC1 | |
| SCHEMBL19874766 | 0.71 | DPP8 (0.35) | SLC1A3SLC1A2SLC1A1DPP8DPP7 | |
| SCHEMBL3315020 | 0.70 | — | — | |
| SCHEMBL2773399 | 0.70 | RAB9A (0.40) | RBP4RAB9ANPC1 | |
| SCHEMBL15390149 | 0.70 | RAB9A (0.40) | RBP4RAB9ANPC1 | |
| SCHEMBL12016032 | 0.69 | GNAI3 (0.45) | ITGB3ITGA2B | |
| SCHEMBL796623 | 0.69 | ALDH1A1 (0.36) | SLC1A3SLC1A2SLC1A1ITGB3ITGA2B | |
| SCHEMBL155583 | 0.69 | EPHX2 (0.41) | DPP8DPP7ALDH1A1L3MBTL1NPC1 | |
| SCHEMBL3160989 | 0.68 | TACR3 (0.36) | SLC1A3SLC1A2SLC1A1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1366066-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | MAPK1 251/4885SMN1; SMN2 3682/4885SLC1A3 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.